New Delhi: Giving some relief to cancer patients, pharma major Cipla today slashed prices of its three generic cancer drugs by up to 64 per cent. Drugs under the brand names Erlocip, Docetax and Capegard are used for treating lung and pancreatic cancer, breast cancer, head & neck cancer, gastric cancer, bladder, colorectal and colon cancers, Cipla said. Lung cancer drug Erlocip will now cost Rs 9,900 for thirty tablets against its earlier price of Rs 27,000, while Docetax used for treating breast cancer, head & neck cancer, gastric cancer and bladder cancer will now cost Rs 1,650 from its earlier price of Rs 3,300, it added. Capegard, another cancer drug that treats breast, colon and colorectal cancer will now be available at Rs 600 for 10 tablets from its earlier price of Rs 1,200, it added. "Continuing its contribution towards affordable and accessible treatment for patients, Cipla extends the work done in HIV/AIDS and malaria to now includes cancer, not only in India but globally," Cipla Chairman and Managing Director Y K Hamied said. Incidentally in September this year, the Delhi High Court had held that Cipla had not infringed upon the patent right of Swiss drug company F Hoffman La-Roche on a cancer drug.
Meth `may help fight flu virus`
Brain`s metabolism can predict Alzheimer`s progress: Study